Ich suche nach...

Logo des Universitätsklinikums Regensburg

Klinik und Poliklinik für Innere Medizin III
Hämatologie und Internistische Onkologie

Arbeitsgruppe Prof. Dr. D. Wolff

cGvHD - NIH Consensus Projekt Immunmonitoring und Biomarker der cGvHD

Die Arbeitsgruppe chronische GVHD unter Leitung von Prof. Dr. Daniel Wolff beschäftigt sich mit klinischen und experimentellen Arbeiten zur chronischen GVHD. Die Gruppe betreibt zusammen mit dem Deutsch-Österreich-Schweizer GVHD-Consortium (www.gvhd.de) ein GVHD-Register, in dem der klinische Verlauf aller Patienten mit später akuter und chronischer GVHD dokumentiert wird. Weiterhin leitet Prof. Dr. Daniel Wolff ein multidisziplinäres Team (GVHD-Zentrum), welches Patienten des eigenen Transplantationsprogramms aber auch zahlreiche Patienten aus Deutschen und Europäischen Zentren im Rahmen einer Zweitmeinungsvorstellung betreut. Weitere Schwerpunkte sind die Entwicklung neuer Tools zur standardisierten Dokumentation von Comorbiditäten und der chronischen GVHD in Kooperation mit Industrie-Partnern. Im von der Deutschen-Forschungsgemeinschaft geförderten Transregio 221 beschäftigt sich die Arbeitsgruppe mit der Rolle von B-Zell-Subpopulationen bei der Pathophysiologie der chronischen GVHD. Weitere Schwerpunkte sind die klinische Validierung von Impfempfehlungen sowie die Entwicklung von prognostischen und prädiktiven Biomarkern bei Patienten mit chronischer GVHD. Ein letzter Schwerpunkt ist die Analyse von sozioökonomischen Aspekten der allogenen Blutstammzelltransplantation.

  • Ausgewählte Publikationen:
    • Wolff, D. Fatobene, G. Rocha, V. Kroger, N., Flowers, M. E. Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transplant 2021, 56; 2079-2087
    • Wolff, D., Radojcic, V., Lafyatis, R., Cinar, R., Rosenstein R.K. Cowen, E.W, Cheng, G.-S., Sheshadri, A. Bergeron, A. Williams, K.M., Todd, J.L. Teshima, T., Cuvelier, G.D.E, Holler, E., McCurdy, S.R., Jenq, R.R. Hanash, A.M., Jacobsohn, D., Santomasso, B.D.,,Jain, S., Ogawa, Y., Steven, P., , Luo, Z.K., Dietrich-Ntoukas, T., Saban, D., Bilic, E., Penack, O., Griffith, L., Cowden, M., Martin, P.J., Greinix, H.T., Sarantopoulos, S., Socie, G., Blazar, B.R., Pidala, J., Kitko, C.L., Couriel, D.R., Cutler, C., Schultz, K.R., Pavletic, S.Z., Lee, S.J., Paczesny, S.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. TCT, 2021: 27; 817-835
    • Parisek, M., J. Loss, J., Holler, E., Barata, A., Weber, D., Edinger, M., Wolff, D., Herr, W., Schoemans, H., Herrmann, A. “This Graft versus Host Disease Determines my Life. That’s it.” – A Qualitative Analysis of the Experiences and Needs of Allogenic Hematopoietic Stem Cells Transplantation Survivors in Germany. Frontiers in Public Health 2021
    • Sattler, S., Hoffmann, P., Herzberg, P.Y., Weber, D., Holler, B., Fehn, U., Plentz, A., Beckhove, P., Winkler, J., Edinger, M., Herr, W., Holler, E., Wolff, D.. Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - a single center retrospective efficacy analysis. Vaccine 202; 39: 4742-4750
    • Wagner-Drouet, E., Teschner, D., Wolschke, C., Schäfer-Eckart, K., Gärtner, J., Mielke, S., Schreder, M., Kobbe, G., Hilgendorf, I., Klein, S., Verbeek, M., Ditschkowski, M., Koch, M., Lindemann, M., Schmidt, T., Rascle, A., Barabas, S., Deml, L., Wagner, R., Wolff, D. Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. Diagnostics 2021: 11
    • Toenges, R, Greinix, H., Lawitschka, A., Halter, J., Baumgartner, A., Simon, A., Arends, J., Jäger, P., Middeke, M., Hilgendorf, I., Klein, S., Wagner, E.M., Schmid, C., Bug, G., Wolff, D., Current practice in nutrition after allogeneic hematopoietic stem cell transplantation – results from a survey among German-Austrian-Swiss allogeneic hematopoietic stem cell transplant centers. Clinical Nutrition 2021 ; 40: 1571-1577
    • Wertheimer, T., Fante, M., Dohse, M., Mielke, S., Afram, G., Ljungman, P., Pérez Martínez, A., Weber, D., Holler, B., Kattner, A.-S., Holler, E., Holler, B., Herr, W., Edinger, M., Wolff, D. Abatacept as salvage therapy in the treatment of chronic graft-versus-host disease- a retrospective analysis. Annals of Hematol 2021; 100: 779-787
    • Wolff, D, Bardak, J. Edinger, M., Klinger-Schindler, U., Holler, E., Lawitschka, L., Schoemans, H., Herr, W., Kröger, N., Ayuk. Evaluation of the cost of survivorship care after allogeneic hematopoeitic stem cell transplantation - an analysis of 2 German transplantation centres. Frontiers in Public Health, section Health Economics 2020.
    • : Fante, M.A., Holler, B., Weber, D., Angstwurm, K., Bergler, T. Holler, E., Edinger, M., Herr, W., Wertheimer, T., Wolff, D. Cyclophosphamide for salvage therapy of chronic Graft-versus-Host Disease: A retrospective analysis. Annals of Hematol 2020: 99: 2181-2190
    • Wolff, D., Herzberg, P.Y., Herrmann, A., Pavletic, S.Z., Heussner, P., Mumm, F., Höfer, C., Hilgendorf, I., Hemmati, P.G, Holler, E., Greinix, H., Mitchell, S.A. Post-Transplant Multimorbidity Index and Quality of Life in Patients with Chronic Graft-versus-Host Disease – Results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transplant 2021, 56; 2618
    • Kattner, A.-S., Holler, E., Holler, B., Klobuch, S., Weber, D., Martinovic, D., Edinger, M., Herr, W., Wolff, D. IL6-receptor antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Annals of Hematology 2020; 99: 847-853
    • Wagner-Drouet, E., Teschner, D., Wolschke, C., Janson, D., Schafer-Eckart, K., Gartner, J., Mielke, S., Schreder, M., Kobbe, G., Kondakci, M., Hilgendorf, I., von Lilienfeld-Toal, M., Klein, S., Heidenreich, D., Kreil, S., Verbeek, M., Grass, S., Ditschkowski, M., Gromke, T., Koch, M., Lindemann, M., Hunig, T., Schmidt, T., Rascle, A., Guldan, H., Barabas, S., Deml, L., Wagner, R., Wolff, D. Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. Haematologica 2021; 106: 363-374
    • Klobuch, S., Weber, D., Holler, B., Edinger, M., Herr, W., Holler, E., Wolff, D. Long-term follow-up of rituximab in treatment of chronic graft-versus-host disease - single center experience. Annals of Hematology 2019; 98: 2399-2405.
    • Wolff, D., Hilgendorf, I., Wagner-Drouet, E., Jedlickova, Z., Ayuk, F., Zeiser, R., Schäfer-Eckart, K., Gerbitz, A., Stadler, M., Klein, S., Middeke, J.-M., Lawitschka, A., Winkler, L., Halter, J., Holler, E., Kobbe, G., Stelljes, M., Ditschkowski, M., Greinix, H. Changes in immunosuppressive treatment of chronic graft-versus-host disease – comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria and Switzerland, B&BMT 2019; 25: 1450-1455
    • Lamby, P., Wolff, D., Mielke, S., Grigoleit, G.U., Ljungman, P., Hilgendorf, I., Holler, E., Holler, B., Weber, D., Herr, W., Schiltz, D., Klein, S., Graf, S., Bjornhagen-Safwenberg, V., Dolderer, J., Prantl, L. Allogeneic donor split skin grafts for treatment of refractory ulcers in cutaneous chronic Graft-versus-Host Disease after allogeneic hematopoietic stem cell transplantation – a retrospective analysis on 7 patients. Annals of Hematology 2019; 98: 1867-1875
    • Wolff, D., Greinix, H., Lee, S.J., Gooley, T., Paczesny,S., Pavletic, S., Hakim, F., Malard, F., Jagasia, M., Lawitschka, A., Hansen, J.A., Pulanic, D., Holler, E., Dickinson, A., Weissinger, E., Edinger, M., Sarantopoulos, S., Schultz. K.R.  Biomarkers in chronic graft-versus-host disease – quo vadis? Bone Marrow Transplant 2018; 53: 832-837
    • Bohmann, E.M., Fehn, U., Holler, B., Weber, D., Holler, E., Herr, W., Hoffmann, P., Edinger, M., Wolff, D. Altered immune-reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset. Annals of Hematology 2017; 96: 299-310
    • Ullrich, E., Salzmann-Manrique, E., Bakhtiar, S., Bremm, M., Gerstner, S., Herrmann, E., Bader, P., Hoffmann, P., Holler, E., Edinger, M., Wolff, D. Relation between acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation. Frontiers in Immunology 2016; 7: 595
    • Grube, M., Holler, E., Weber, D., Holler, B., Herr, W., Wolff, D. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. Biol. Blood & Marrow Transplant 2016; 22: 1781-1791.
    • Kariminia, A., Holtan, S.G., Ivison, S., Rozmus, J., Hebert, M.-J., Martin, P.J., Lee, S.J., Wolff, D., Subrt, P., Abdossamadi, S., Sung, S., Storek, J., Levings, M., Aljurf, M.D., Arora. M., Cutler, C., Gallagher, G., Kuruvilla, J., Lipton, J., Nevill, T.J., Newell, L.F., Pidala, J., Popradi, G., Szwajcer, D., Tay, J., Toze, C.L., Walker, I., Couban, S., Storer, B.E., Schultz, K.R. Heterogeneity of Chronic Graft-versus-Host Disease Biomarkers: CXCL10 Is Most Significant And Related To CXCR3+ CD56bright NK Cells. Blood 2016; 127: 3082-91
    • Hilgendorf, I., Greinix, H., Halter, J.P., Lawitschka, A., Bertz, H., Wolff, D. Long-term follow-up after allogeneic stem cell transplantation. Deutsches Ärzteblatt, 2015; 4: 51-58
    • Mielke, S., Lutz, M., Schmidhuber, J., Kapp, M., Ditz, D., Ammer, J., Einsele, H., Grigoleit, G.U. Holler, E., Wolff, D. Salvage therapy with everolimus reduces the severity of treatment-refractory chronic graft-versus-host disease without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplant 2014; 49: 1412-1418.
    • Wolff, D., Ayuk, F., Elmaagacli, A., Bertz, H., Lawitschka, A., Schleuning, M., Meyer, R.G., Gerbitz, A., Hilgendorf, I., Hildebrandt, G.C., Edinger, M., Klein, S., Holler, E., Greinix, H. Current practice in diagnosis and treatment of acute graft-versus-host disease – results from a survey among German-Austrian-Swiss transplantation centers. Biology of Blood and Marrow Transplantation, 2013; 19: 767-776
    • Bouazzaoui A., Dickhöfer, S., Kreuz, M., Huber, E., Andreesen, R., Holler, E., Wolff, D. Conditioning by Treosulfan or Busulfan in combination with Fludarabin reduces acute graft versus host disease (GVHD) and improves survival compared to total body irradiation after experimental bone marrow transplantation. Immunopharmacology and Immunotoxicology 2014; 36: 158-164
    • Herzberg, P.Y., Lee, S.J., Heussner, P., Mumm, F.A.H., Hilgendorf, I., von Harsdorf, S., Hemmati, P., Rieger, K., Greinix, H., Freund, M., Holler, E., Wolff, D. Personality influences Quality of Life Assessments in Patients after allogeneic Hematopoietic Stem Cell Transplantation – Results from a joint Evaluation of the Prospective German Multicenter Validation Trial and the Fred Hutchinson Cancer Research Center. Bone Marrow Transplantation 2013; 48: 129-134
    • Dietrich, T., Cursiefen, C., Westekemper, H., Eberwein, P., Bertz, H., Nepp, J., Basara, N., Greinix, H., Datiles, M.B., Lee, S.J., Pavletic, S.Z., Wolff, D. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): Diagnosis and treatment of ocular chronic GVHD. Cornea 2012; 31: 299-310
    • Roll, D., Ammer, J., Holler, B., Salzberger, B., Schweiger, B., Jilg, W., Wolff, D., Andreesen, R., Edinger, M., Holler, E. Vaccination against H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation - a retrospective analysis. Infection 2012; 40: 153-161
    • Kramer, M., Heussner, P., Herzberg, P.Y., Andree, H., Hilgendorf, I., Leithaeuser, M., Junghanss, C., Freund, M., Wolff, D. GVHD impairs Physical Performance and Quality of Life – Results from a prospective Trial on Physical Performance and Quality of Life during the first 3 months after allogeneic Hematopoietic Stem cell Transplantation. Support Care Cancer, 2013; 21: 1121-1129
    • Hilgendorf, I., Mueller-Hilke, B., Kundt, G., Holler, E., Hoffmann, P., Edinger, M., Freund, M., Wolff, D. Chronic GVHD is associated with a lack of T cell independent IgM+IgD+ memory B cells. Transplantation Int., 2011; 25: 87-96

Kontakt

Prof. Dr. Daniel Wolff
Klinik und Poliklinik für Innere Medizin III
Universitätsklinikum Regensburg
Franz-Josef-Strauß Allee 11, 93053 Regensburg
0941 944-5542 / -15531
0941 944-5543
daniel.wolff@ukr.de